EA201991357A1 - Применение ингибиторов ил-8 в лечении некоторых урологических расстройств - Google Patents
Применение ингибиторов ил-8 в лечении некоторых урологических расстройствInfo
- Publication number
- EA201991357A1 EA201991357A1 EA201991357A EA201991357A EA201991357A1 EA 201991357 A1 EA201991357 A1 EA 201991357A1 EA 201991357 A EA201991357 A EA 201991357A EA 201991357 A EA201991357 A EA 201991357A EA 201991357 A1 EA201991357 A1 EA 201991357A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitors
- treatment
- application
- urological disorders
- chronic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17150176.0A EP3342407A1 (en) | 2017-01-03 | 2017-01-03 | Il-8 inihibitors for use in the treatment of some urological disorders |
| PCT/EP2018/050009 WO2018127469A1 (en) | 2017-01-03 | 2018-01-02 | Il-8 inihibitors for use in the treatment of some urological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991357A1 true EA201991357A1 (ru) | 2019-12-30 |
Family
ID=57758480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991357A EA201991357A1 (ru) | 2017-01-03 | 2018-01-02 | Применение ингибиторов ил-8 в лечении некоторых урологических расстройств |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190336484A1 (https=) |
| EP (2) | EP3342407A1 (https=) |
| JP (1) | JP2020503267A (https=) |
| KR (1) | KR20190102177A (https=) |
| CN (1) | CN109937037A (https=) |
| AU (1) | AU2018206134A1 (https=) |
| BR (1) | BR112019009588A2 (https=) |
| CA (1) | CA3046531A1 (https=) |
| EA (1) | EA201991357A1 (https=) |
| IL (1) | IL267577A (https=) |
| MA (1) | MA47199A (https=) |
| MX (1) | MX2019007972A (https=) |
| WO (1) | WO2018127469A1 (https=) |
| ZA (1) | ZA201902427B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212051A4 (en) * | 1999-08-27 | 2004-03-31 | Merck & Co Inc | METHOD FOR TREATING OR PREVENTING CHEMICAL PROSTATITIS OR CHRONIC POOL PAIN |
| PL1776336T3 (pl) | 2004-03-23 | 2010-06-30 | Dompe Farm Spa | Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| WO2010078403A2 (en) | 2008-12-30 | 2010-07-08 | Lipella Pharmaceuticals Inc. | Methods and compositions for diagnosing urological disorders |
| US20120076791A1 (en) * | 2010-09-29 | 2012-03-29 | Philip Bosch | Methods Of Treating Chronic Prostatitis/Chronic Pelvic Pain Syndrome |
| CN105582134A (zh) * | 2014-09-12 | 2016-05-18 | 青岛华之草医药科技有限公司 | 一种治疗前列腺炎的中药组合物 |
| EP3117835A1 (en) * | 2015-07-14 | 2017-01-18 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment of certain urological disorders |
-
2017
- 2017-01-03 EP EP17150176.0A patent/EP3342407A1/en not_active Withdrawn
-
2018
- 2018-01-02 WO PCT/EP2018/050009 patent/WO2018127469A1/en not_active Ceased
- 2018-01-02 EP EP18701088.9A patent/EP3565545A1/en not_active Withdrawn
- 2018-01-02 MX MX2019007972A patent/MX2019007972A/es unknown
- 2018-01-02 CA CA3046531A patent/CA3046531A1/en not_active Abandoned
- 2018-01-02 MA MA047199A patent/MA47199A/fr unknown
- 2018-01-02 KR KR1020197013259A patent/KR20190102177A/ko not_active Ceased
- 2018-01-02 CN CN201880003982.6A patent/CN109937037A/zh active Pending
- 2018-01-02 BR BR112019009588A patent/BR112019009588A2/pt not_active Application Discontinuation
- 2018-01-02 JP JP2019528129A patent/JP2020503267A/ja not_active Withdrawn
- 2018-01-02 US US16/475,166 patent/US20190336484A1/en not_active Abandoned
- 2018-01-02 EA EA201991357A patent/EA201991357A1/ru unknown
- 2018-01-02 AU AU2018206134A patent/AU2018206134A1/en not_active Abandoned
-
2019
- 2019-04-16 ZA ZA2019/02427A patent/ZA201902427B/en unknown
- 2019-06-23 IL IL267577A patent/IL267577A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018127469A1 (en) | 2018-07-12 |
| IL267577A (en) | 2019-08-29 |
| KR20190102177A (ko) | 2019-09-03 |
| MX2019007972A (es) | 2019-09-09 |
| EP3342407A1 (en) | 2018-07-04 |
| MA47199A (fr) | 2019-11-13 |
| JP2020503267A (ja) | 2020-01-30 |
| BR112019009588A2 (pt) | 2019-08-06 |
| CA3046531A1 (en) | 2018-07-12 |
| AU2018206134A1 (en) | 2019-05-23 |
| CN109937037A (zh) | 2019-06-25 |
| EP3565545A1 (en) | 2019-11-13 |
| US20190336484A1 (en) | 2019-11-07 |
| ZA201902427B (en) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092590A1 (ru) | Пиридазиноны в качестве ингибиторов parp7 | |
| PH12021552856A1 (en) | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| EA202191122A1 (ru) | СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ | |
| MX384792B (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| MX391720B (es) | Terapia combinada para tratar cáncer. | |
| EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
| EA202090572A1 (ru) | ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ | |
| EA201691114A1 (ru) | Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии | |
| EA201690456A1 (ru) | Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов | |
| EA201992721A1 (ru) | Способы получения и применения ингибиторов pde9 | |
| EA201170288A1 (ru) | Оксабициклогептаны и оксабициклогептены, их получение и применение | |
| MX2021015826A (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| EA201891946A1 (ru) | Коагонисты глюкагона и glp-1 для лечения ожирения | |
| HUE054137T2 (hu) | NX-1207 jóindulatú prosztatamegnagyobbodásban szenvedõ páciensek kezelésében sebészeti beavatkozás szükségességének csökkentésére történõ alkalmazásra | |
| ECSP045021A (es) | Terapia de combinacion para el tratamiento del cancer | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| EA201991395A1 (ru) | Новые композиции для лечения суставных нарушений | |
| EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы | |
| EA201892672A1 (ru) | Лечение боли | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| EA201991357A1 (ru) | Применение ингибиторов ил-8 в лечении некоторых урологических расстройств | |
| EA202091524A1 (ru) | Ингибиторы рецептора, активируемого протеазой 2 |